Dr. Goel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
AECOM
1825 Eastchester Rd
Bronx, NY 10461Phone+1 718-904-2488Fax+1 718-904-2830
Education & Training
- Albert Einstein College of MedicineM.S., Clinical Research Methodology, 2001 - 2003
- Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 2000 - 2002
- Albert Einstein College of MedicineFellowship, Hematology, Oncology, 2000 - 2002
- University of ColoradoFellowship, Hematology and Medical Oncology, 1999 - 2000
- University of Colorado Health Sciences CenterFellowship, Hematology, Oncology, 1999 - 2000
- SUNY Downstate Health Sciences UniversityResidency, Internal Medicine, 1996 - 1999
- Christian Medical College VelloreClass of 1995
Certifications & Licensure
- NY State Medical License 2002 - 2026
- NJ State Medical License 2022 - 2025
- VA State Medical License 2002 - 2008
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Translational Research Award ECOG Young Investigators Symposium, 2007
- Best Faculty Teaching 2005
- Best Presentation Glaxo Smith-Kline National Oncology Fellows Forum, 2002
- Join now to see all
Clinical Trials
- Exploratory Study Of The ERCC-1 Gene Start of enrollment: 2008 Feb 01
- A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint Start of enrollment: 2008 Sep 01
- A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies Start of enrollment: 2009 Dec 11
- Join now to see all
Publications & Presentations
PubMed
- Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer.Harshabad Singh, Joanne Xiu, Kevin S Kapner, Chen Yuan, Raja R Narayan
Clinical Cancer Research. 2024-11-01 - Mesothelin expression correlates with elevated inhibitory immune activity in patients with colorectal cancer.Midhun Malla, Sachin Kumar Deshmukh, Sharon Wu, Timothy Samec, Dane C Olevian
Cancer Gene Therapy. 2024-10-01 - Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer.Shubham Pant, Byoung Chul Cho, Christos E Kyriakopoulos, Alexander Spira, Nizar Tannir
Investigational New Drugs. 2024-10-01
Journal Articles
- Therapeutic Targeting of CPT-11 Induced Diarrhea: A Case For Prophylaxis.Swami U, Goel S, Mani S, Curr Drug Targets, 4/15/2013
- Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy.Aparo S, Goel S, Crit Rev Oncol Hematol, 7/1/2012
- Eribulin-A review of preclinical and clinical studies.Swami U, Chaudhary I, Ghalib MH, Goel S, Crit Rev Oncol Hematol, 2/1/2012
- Join now to see all
Abstracts/Posters
- Tumor BiologyGoel S, 47th Annual Meeting of the American Society of Clinical Oncology, 6/1/2011
- “PIK3CA/PTEN mutation status predicts response of the colon cancer cells to the EGFR inhibitor cetuximab”Goel S, Jhawer M, Wilson AJ, et al, 2007 ECOG Young Investigators Symposium in Fort Lauderdale, FL, 1/1/2007
- Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamcis of Ixabepilone.Goel S, Goldberg G, Iacono L, et al, ASCO Annual Meeting Proceedings Part I, 6/20/2006
- Join now to see all
Lectures
- Assessing Response to Therapy: Radiographic Response Criteria Review2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018
- Colorectal Cancer: Updates and Future DirectionsDepartment of Pathology, Assam Medical College, Dibrugah, Assam, India - 10/1/2010
- Updates in Colorectal CancerGrand Rounds, Department of Surgery, Montefiore Medical Center, Albert Einstein College of Medicine - 12/1/2006
- Join now to see all
Press Mentions
- Neil Palmisiano, MD, Appointed as Deputy Director of Phase 1 Therapeutics for Hematologic Malignancies at Rutgers Cancer Institute of New JerseyOctober 3rd, 2022
- Benefit of Biologic Agents in mCRC Is Color-BlindDecember 16th, 2021
- Black Family Cancer Awareness Week Blog Q&AJune 16th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: